GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corestemchemon Inc (XKRX:166480) » Definitions » Current Deferred Revenue

Corestemchemon (XKRX:166480) Current Deferred Revenue : ₩0 Mil (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Corestemchemon Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Corestemchemon's current deferred revenue for the quarter that ended in Mar. 2025 was ₩0 Mil.

Corestemchemon Current Deferred Revenue Historical Data

The historical data trend for Corestemchemon's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corestemchemon Current Deferred Revenue Chart

Corestemchemon Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Corestemchemon Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Corestemchemon Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Corestemchemon's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Corestemchemon Business Description

Traded in Other Exchanges
N/A
Address
Pangyo 255 beongil 24 I & C Building, 2nd Floor, yeonggi-do, Bundang-gu, Seongnam, Seoul, KOR, 13486
Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.

Corestemchemon Headlines

No Headlines